These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 7749136)
1. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Iwase H; Kobayashi S; Itoh Y; Fukuoka H; Kuzushima T; Iwata H; Yamashita T; Naitoh A; Itoh K; Masaoka A Breast Cancer Res Treat; 1995; 33(1):83-8. PubMed ID: 7749136 [TBL] [Abstract][Full Text] [Related]
2. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034 [TBL] [Abstract][Full Text] [Related]
3. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer]. Kaneko Y; Imoto S; Kasakura S Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542 [TBL] [Abstract][Full Text] [Related]
4. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854 [TBL] [Abstract][Full Text] [Related]
5. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients. Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655 [TBL] [Abstract][Full Text] [Related]
6. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. Shao Y; Sun X; He Y; Liu C; Liu H PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909 [TBL] [Abstract][Full Text] [Related]
7. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529 [TBL] [Abstract][Full Text] [Related]
8. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872 [TBL] [Abstract][Full Text] [Related]
9. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis. Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173 [TBL] [Abstract][Full Text] [Related]
10. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247 [TBL] [Abstract][Full Text] [Related]
11. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Kurebayashi J; Nishimura R; Tanaka K; Kohno N; Kurosumi M; Moriya T; Ogawa Y; Taguchi T Breast Cancer; 2004; 11(4):389-95. PubMed ID: 15604995 [TBL] [Abstract][Full Text] [Related]
12. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor. El-Attar NI; Gaefar HA Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663 [TBL] [Abstract][Full Text] [Related]
13. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients. Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361 [TBL] [Abstract][Full Text] [Related]
14. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis. Fu Y; Li H Med Sci Monit; 2016 Sep; 22():3154-62. PubMed ID: 27596019 [TBL] [Abstract][Full Text] [Related]
15. [Clinical usefulness of tumor markers in breast cancer]. Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956 [TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry. Nam SE; Lim W; Jeong J; Lee S; Choi J; Park H; Jung YS; Jung SP; Bae SY Breast Cancer Res Treat; 2019 Oct; 177(3):669-678. PubMed ID: 31312932 [TBL] [Abstract][Full Text] [Related]
17. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Samy N; Ragab HM; El Maksoud NA; Shaalan M Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232 [TBL] [Abstract][Full Text] [Related]
19. [Serum concentration of selected neoplasm markers: CA15-3, TPS and CEA in women with diagnosed breast benign disease]. Kochańska-Dziurowicz A; Pasich R; Stanjek A; Gaweł-Szostek V; Jankowski T Ginekol Pol; 2000 Sep; 71(9):1139-43. PubMed ID: 11082991 [TBL] [Abstract][Full Text] [Related]
20. Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study. Kurebayashi J; Yamamoto Y; Tanaka K; Kohno N; Kurosumi M; Moriya T; Nishimura R; Ogawa Y; Taguchi T; Breast Cancer; 2003; 10(1):38-44. PubMed ID: 12525762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]